Home/Pipeline/LIAISON® Calprotectin

LIAISON® Calprotectin

Inflammatory Bowel Disease (IBD)

CommercialLaunched

Key Facts

Indication

Inflammatory Bowel Disease (IBD)

Phase

Commercial

Status

Launched

Company

DiaSorin

About DiaSorin

DiaSorin's mission is to improve healthcare through a broad portfolio of high-quality, specialized immunodiagnostic solutions. A key achievement was the transformative $1.8 billion acquisition of Luminex in 2021, which expanded its technological capabilities into molecular diagnostics and significantly strengthened its North American presence. The company's strategy rests on three pillars: continuous innovation of its proprietary LIAISON® platform, strategic M&A to broaden its test menu and geographic reach, and direct commercial engagement in key markets to drive its razor-and-blade business model.

View full company profile

Therapeutic Areas

Infectious Diseases Endocrinology Gastrointestinal Diseases Autoimmune Diseases Metabolic Disorders Oncology

Other Inflammatory Bowel Disease (IBD) Drugs

Drug	Company	Phase	Status
HBM2001	Harbour BioMed	Discovery	Active (Global)
Metabolite Delivery Platform (Therapeutic Programs)	ClostraBio	Pre-clinical	Platform Development
ABO21009	AboleIIs Pharma	Phase 1	Planned/Preclinical
GlyHealth Biomarkers	Avenna	Pre-clinical/Validation	Active
GTI-850	GSNO Therapeutics	Pre-clinical	Active
CK-0045	Cytoki Pharma	Pre-clinical/Research	Active
MV-010	MV BioTherapeutics	Preclinical	Active
NM81	Numab Innovation	Pre-clinical	Active (Licensed to Kaken)
SL-325	Shattuck Labs	Phase 2	Active
SL-425	Shattuck Labs	Phase 1	Active
VE202	PureTech Health	Phase 2	Active